Esperion Therapeutics, Inc. 8-K

What Happened
Esperion Therapeutics, Inc. announced that on May 1, 2026 it entered into an Agreement and Plan of Merger with Essence Parent Inc. (an affiliate of ArchiMed SAS) and MergerCo, under which MergerCo will merge into Esperion and Esperion will become a wholly owned subsidiary of Parent if closing conditions are met. The Hart-Scott-Rodino (HSR) antitrust waiting period expired at 11:59 p.m. ET on June 15, 2026. The transaction still requires other customary closing conditions, including approval by Esperion stockholders at a virtual special meeting scheduled for July 8, 2026 at 8:00 a.m. ET. The company filed a Schedule 14A proxy statement relating to the vote and has mailed the proxy materials to shareholders.

Key Details

• Merger Agreement signed: May 1, 2026, parties: Esperion, Essence Parent Inc. (ArchiMed affiliate), and Essence MergerCo Inc.
• Regulatory milestone: HSR waiting period expired June 15, 2026 at 11:59 p.m. ET.
• Stockholder vote: Special virtual meeting scheduled for July 8, 2026 at 8:00 a.m. ET to consider adoption of the Merger Agreement.
• Transaction economics/contingent rights: The filing references contingent value rights (CVRs) tied to net sales milestones; holders may receive payments only if milestones are met.
• Proxy: Schedule 14A proxy statement has been filed and mailed; available on EDGAR and Esperion’s investor site.

Why It Matters
This filing confirms the antitrust waiting period clearance step for Esperion’s proposed take-private acquisition by an ArchiMed affiliate, bringing the deal closer to completion but still subject to shareholder approval and other closing conditions. If approved and closed, Esperion would become a privately held subsidiary, which could affect the company’s public reporting, share liquidity, management direction, and potential future payouts to holders of CVRs tied to product net sales. Investors should review the proxy materials for details on the vote, transaction terms, and the CVR milestones, and note the company’s forward-looking disclosures about risks and timing.